Exscientia’s Centaur Chemist™ Artificial Intelligence-powered platform has been validated by some of the world’s leading pharma companies and has the potential to initiate up to 20 projects per year. Since our foundation in 2012, we have entered into nine pharma collaborations and co-development projects, details of which you can find below. We are also developing our own pipeline projects to help get the right drugs to the right patients faster.
Accelerating the discovery of small molecule therapeutic drug candidates in oncology and autoimmunity.
Designing bispecific small molecules for metabolic disease.
Sumitomo Dainippon Pharma
Delivering advanced molecules to accelerate central nervous system drug discovery.
Discovering and optimising novel medicines for psychiatric disorders.
Uncovering novel and selective small molecules for up to ten disease-related targets.
Designing pre-clinical drug candidates in oncology.
Discovering and developing first-in-class bispecific small molecule immuno-oncology therapies.
GT Apeiron Therapeutics
Fast-tracking the development of novel drugs to tackle high impact therapeutic targets in oncology.
Developing small molecule drug therapeutics and pre-clinical drug candidates for rare diseases.
Our projects in this area modulate the suppressive impact of metabolites in the tumour microenvironment on immune cells.
Our portfolio focuses on fast breaking targets that are also small molecule druggable.
Our portfolio focuses on some of the most recent target discoveries focusing on anti-inflammatory and anti-fibrotic mechanisms.
Partner with us
We use our creative team and cutting-edge AI technology in partnership with world-class life science industry leaders and resources to create a new standard of drug discovery.
We are always on the lookout for new collaborations that support and help our mission to deliver faster, better treatments for patients all over the world.
Contact us to discuss partnership opportunities.